Screener
Emergent Biosolutions EBS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001367644-26-000082
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accrued compensation | (16.0) | (26.3) |
| Income taxes receivable and payable, net | 4.3 | (1.6) |
| Contract liabilities | 6.5 | (0.1) |
| Net cash provided by operating activities | 22.3 | 95.2 |
| Investing Activities | ||
| Purchases of property, plant and equipment | (4.5) | (6.5) |
| Proceeds from sale of property, plant and equipment | 0.2 | 38.2 |
| Milestone payment from prior asset acquisition | (50.4) | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Emergent Biosolutions's operating cash flow?
- Emergent Biosolutions (EBS) reported operating cash flow of $56.1M in Q2 2026.
- How has Emergent Biosolutions's operating cash flow changed year-over-year?
- Emergent Biosolutions's operating cash flow decreased by 47.3% year-over-year, from $106.4M to $56.1M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Emergent Biosolutions's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude